Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
150 hedge funds and large institutions have $1.95B invested in Verona Pharma in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 42 increasing their positions, 48 reducing their positions, and 19 closing their positions.
132% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 19
104% more capital invested
Capital invested by funds: $957M → $1.95B (+$993M)
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
20% more funds holding
Funds holding: 125 → 150 (+25)
0.61% less ownership
Funds ownership: 11.02% → 10.41% (-0.61%)
12% less call options, than puts
Call options by funds: $24.3M | Put options by funds: $27.6M
13% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$95.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$46.7M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
+$27.6M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$27.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$26.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$64.6M |
| 2 |
O
OrbiMed
New York
|
-$41.4M |
| 3 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$35.5M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$20.2M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$15.2M |
VRNA Hedge Fund Activity: Q3 2024 in Review
150 of the 6,910 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2024, worth a combined $1.95B — up 104% from $957M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new VRNA positions and 19 closed out — a net gain of 25 holders — while 42 added to existing stakes and 48 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $95.5M. The largest seller was RA Capital Management, cutting an estimated $64.6M.
- 150 institutional investors held Verona Pharma (VRNA) as of Q3 2024, up from 125 in Q2 2024.
- Funds reported $1.95B of Verona Pharma stock for Q3 2024, up 104% quarter-over-quarter.
- 44 funds opened new Verona Pharma positions in Q3 2024 and 19 closed out, a net change of +25 holders.
- The largest Verona Pharma buyer in Q3 2024 was Perceptive Advisors, an estimated $95.5M added.
- The largest Verona Pharma seller in Q3 2024 was RA Capital Management, an estimated $64.6M sold.
Based on aggregated 13F filings for Q3 2024.